Biossil Overview
- Year Founded
-
2023
- Status
-
Private
- Employees
-
30
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$153M
- Investors
-
13
Biossil General Information
Description
Developer of an artificial intelligence drug discovery platform designed to offer targeted therapies for biologically defined patient sub-populations. The company's platform offers excavate, which combines a data-point multi-omics pipeline with population-scale electronic medical record data to translate disease sub-phenotypes into molecular endotypes defined by interactome-scale disease modules, enabling medical researchers to cut drug repurposing time and bring shelved therapies to trial faster.
Contact Information
Website
www.biossil.coCorporate Office
- 435 Richmond Street West
- Toronto, Ontario M5V 0N3
- Canada
Corporate Office
- 435 Richmond Street West
- Toronto, Ontario M5V 0N3
- Canada
Biossil Timeline
Biossil Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC | 28-Sep-2026 | $153M | Completed | Clinical Trials - Phase 2 | ||
| 3. Seed Round | 20-Apr-2026 | Completed | Clinical Trials - Phase 2 | |||
| 2. Seed Round | 01-Jan-2024 | $22M | $25.7M | Completed | Stealth | |
| 1. Seed Round | 11-Sep-2023 | $3.7M | $3.7M | Completed | Stealth |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Biossil Patents
Biossil Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026224624-A1 | Method for treatment or reduction of the incidence of a neural disease | Pending | 21-Apr-2025 | ||
| WO-2026163175-A1 | Use of gardos channel inhibitors and dosing regimens thereof in the treatment of sickle cell disease | Pending | 03-Feb-2025 | ||
| WO-2026163176-A1 | Use of gardos channel inhibitors in the treatment of sickle cell disease | Pending | 03-Feb-2025 | ||
| WO-2026137073-A1 | Adjunct therapy for the treatment of glioblastoma multiforme | Pending | 23-Dec-2024 | ||
| WO-2026137071-A1 | Combination therapy for the treatment of sickle cell disease | Pending | 23-Dec-2024 | A61P3/00 |
Biossil Signals
Biossil Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Abu Dhabi Investment Council | Sovereign Wealth Fund | Minority | ||
| DUMAC (Durham) | Limited Partner | Minority | ||
| OpenAI Startup Fund | Corporate Venture Capital | Minority | ||
| 137 Ventures | Venture Capital | Minority | ||
| DRI Healthcare Trust | Corporation | Minority |
Biossil Investments (4)
Biossil’s most recent deal was a Corporate Asset Purchase with Alligator Bioscience (CD40 Agonist Antibody Mitazalimab) for . The deal was made on 31-Oct-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Alligator Bioscience (CD40 Agonist Antibody Mitazalimab) | 31-Oct-2026 | Corporate Asset Purchase | Buildings and Property | ||
| Summit Therapeutics (Ridinilazole Antibiotic Asset) | 14-Jul-2026 | Corporate Asset Purchase | Buildings and Property | ||
| Galera Therapeutics (Dismutase Mimetics Portfolio in Toronto, Canada) | 22-Oct-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Inventiva Pharma (Global Rights to Odiparcil) | 01-Jan-2025 | Corporate Asset Purchase | Buildings and Property |
Biossil FAQs
-
When was Biossil founded?
Biossil was founded in 2023.
-
Where is Biossil headquartered?
Biossil is headquartered in Toronto, Canada.
-
What is the size of Biossil?
Biossil has 30 total employees.
-
What industry is Biossil in?
Biossil’s primary industry is Decision/Risk Analysis.
-
Is Biossil a private or public company?
Biossil is a Private company.
-
What is the current valuation of Biossil?
The current valuation of Biossil is .
-
What is Biossil’s current revenue?
The current revenue for Biossil is .
-
How much funding has Biossil raised over time?
Biossil has raised $222M.
-
Who are Biossil’s investors?
Abu Dhabi Investment Council, DUMAC (Durham), OpenAI Startup Fund, 137 Ventures, and DRI Healthcare Trust are 5 of 13 investors who have invested in Biossil.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process